Your browser doesn't support javascript.
loading
A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis.
Mak, Lung-Yi; Gane, Ed; Schwabe, Christian; Yoon, Ki Tae; Heo, Jeong; Scott, Russell; Lee, Jeong-Hoon; Lee, Jung Il; Kweon, Young Oh; Weltman, Martin; Harrison, Stephen A; Neuschwander-Tetri, Brent A; Cusi, Kenneth; Loomba, Rohit; Given, Bruce D; Christianson, Dawn R; Garcia-Medel, Eric; Yi, Min; Hamilton, James; Yuen, Man-Fung.
Afiliação
  • Mak LY; Department of Medicine, School of Clinical Medicine, Hong Kong; State Key Laboratory of Liver Research, Queen Mary Hospital, The University of Hong Kong, Hong Kong.
  • Gane E; University of Auckland, Auckland, New Zealand.
  • Schwabe C; New Zealand Clinical Research, Auckland, New Zealand.
  • Yoon KT; Department of Internal Medicine, Pusan National University College of Medicine and Liver Center, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea.
  • Heo J; Department of Internal Medicine, College of Medicine, Pusan National University and Biomedical Research Institute, Pusan National University Hospital, Busan, Republic of Korea.
  • Scott R; Lipid and Diabetes Research, New Zealand Clinical Research, Christchurch, New Zealand.
  • Lee JH; Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Lee JI; Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Kweon YO; Kyungpook National University, Daegu, Republic of Korea.
  • Weltman M; Nepean Hospital, Penrith, Australia.
  • Harrison SA; Pinnacle Clinical Research Center, San Antonio, TX, United States.
  • Neuschwander-Tetri BA; Saint Louis University School of Medicine, St. Louis, MO, United States.
  • Cusi K; University of Florida, Gainesville, FL, United States.
  • Loomba R; NAFLD Research Center, UCSD, Division of Gastroenterology, La Jolla, CA, United States.
  • Given BD; Arrowhead Pharmaceuticals, Inc., Pasadena, CA, United States.
  • Christianson DR; Arrowhead Pharmaceuticals, Inc., Pasadena, CA, United States.
  • Garcia-Medel E; Arrowhead Pharmaceuticals, Inc., Pasadena, CA, United States.
  • Yi M; Arrowhead Pharmaceuticals, Inc., Pasadena, CA, United States.
  • Hamilton J; Arrowhead Pharmaceuticals, Inc., Pasadena, CA, United States.
  • Yuen MF; Department of Medicine, School of Clinical Medicine, Hong Kong; State Key Laboratory of Liver Research, Queen Mary Hospital, The University of Hong Kong, Hong Kong. Electronic address: mfyuen@hku.hk.
J Hepatol ; 78(4): 684-692, 2023 04.
Article em En | MEDLINE | ID: mdl-36513186
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hepatopatia Gordurosa não Alcoólica Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hepatopatia Gordurosa não Alcoólica Idioma: En Ano de publicação: 2023 Tipo de documento: Article